A groundbreaking clinical trial has brought new hope to the field of longevity science by demonstrating that therapeutic plasma exchange (TPE), combined with intravenous immunoglobulin (IVIG), can measurably reduce biological age in humans. Published in the prestigious journal Aging Cell on May 28, 2025, this pioneering single-blind, placebo-controlled study represents a monumental advancement, providing the first rigorous clinical evidence that targeted plasma interventions can influence the molecular underpinnings of aging. The research was conducted through a collaborative effort by Circulate Health, a biotech company dedicated to harnessing plasma-based therapies for improved healthspan and lifespan, alongside the renowned Buck Institute for Research on Aging.
Biological age, a dynamic marker distinct from chronological age, reflects an individual’s physiological state and risk for age-associated diseases. Measuring biological age requires sophisticated tools capable of capturing changes across multiple biological layers. This study utilized a multi-omic approach—integrating data from the epigenome, proteome, metabolome, glycome, and immune system—to generate a comprehensive profile of molecular aging. This allows for a nuanced assessment of how TPE influences not just individual biomarkers, but the complex interplay of pathways that define the aging process.
Therapeutic plasma exchange is a procedure traditionally used to treat autoimmune and hematological disorders by removing and replacing a patient’s plasma, thereby eliminating circulating pathogenic factors. Leveraging this clinical technique in a longevity context, researchers designed a randomized trial to explore how different frequencies and combinations of TPE and IVIG administration impact biological aging indicators. Participants were assigned into four groups: biweekly TPE, biweekly TPE with IVIG, monthly TPE, and a control cohort, providing a robust framework for comparative analysis.
The standout finding of the trial was the significant reduction in biological age among participants receiving the combined TPE-IVIG treatment. On average, these individuals exhibited a biological age decrease of 2.61 years, almost doubling the effect observed in those receiving TPE alone, who showed a reduction of 1.32 years. This result is striking given the notoriously slow pace of biological aging and the difficulty in achieving measurable rejuvenation through non-genetic interventions. By quantifying shifts in hundreds of molecular markers, the team was able to rigorously document this rejuvenation.
Immune system rejuvenation emerged as a key mechanism underlying these benefits. Patients treated with TPE-IVIG displayed marked changes in immune cell populations typically altered by aging, including a reversal of senescence-associated protein accumulation and restoration of youthful immune cell composition. These shifts suggest improved immune surveillance and resilience, potentially enhancing the body’s ability to combat infections and mitigate chronic inflammatory states commonly linked with age-related morbidity.
Interestingly, baseline health status profoundly influenced treatment response. Participants exhibiting poorer initial health indicators—reflected by elevated circulating bilirubin, glucose, and liver enzyme levels—experienced the most pronounced biological age reductions and biomarker improvements. This observation suggests that TPE-IVIG may exert not only preventive but also restorative effects, offering therapeutic potential for individuals with preexisting metabolic or liver impairments as well as for generally healthy individuals, who nonetheless showed gains in physical functions like balance and strength.
The dosing schedule revealed an important nuance: the most significant therapeutic impacts were observed after the first three treatment sessions, with subsequent exchanges yielding diminishing returns. This insight hints at an adaptive response within the body’s molecular networks and raises important questions about optimal treatment regimens. Strategically spacing treatments or combining TPE-based approaches with other interventions might amplify or sustain benefits, a hypothesis ripe for exploration in future studies.
Dr. David Furman, senior author of the study and a leader in biological aging research at the Buck Institute, emphasized the need to move beyond unvalidated "longevity hacks" toward scientifically grounded interventions. He highlighted that this trial provides a template for rigorously assessing the efficacy of plasma exchange to modulate aging pathways directly in human subjects, a critical step previously unattained in the field.
Brad Younggren, CEO and co-founder of Circulate Health, underscored the transformative potential of plasma exchange paired with IVIG, describing it as “a powerful tool for biological age rejuvenation.” He noted that these findings open paths to innovative clinical applications targeting molecular hallmarks of aging, particularly in reducing the burden of inflammation-related disorders, a common denominator in many chronic diseases.
The multi-omics analysis offered unprecedented resolution, mapping thousands of molecular signatures to identify biomarkers predictive of positive treatment outcomes. Through this granular characterization, the researchers established foundational knowledge for personalized longevity medicine, where individual biomarker profiles will guide customized therapeutic strategies. This represents a paradigm shift from one-size-fits-all interventions toward precision healthspan extension.
Eric Verdin, President and CEO of the Buck Institute and co-founder of Circulate, expressed enthusiasm about scaling this research to larger populations. He stressed that expanding access to plasma-based rejuvenation therapies is crucial for translating these breakthroughs into real-world health improvements. Furthermore, ongoing investigations will continue to uncover unmet medical needs that could benefit from these novel interventions.
In summary, this landmark clinical trial establishes therapeutic plasma exchange combined with intravenous immunoglobulin as a scientifically validated approach to biological age reversal. Through meticulous multi-omics profiling, it reveals significant adjustments in molecular and cellular aging processes, improved immune function, and functional gains in physical health. These results propel plasma exchange from a niche therapeutic procedure to a frontline candidate in the evolving arsenal of longevity medicine, promising to fundamentally alter how age-related health declines are addressed.
As the global population ages, innovative interventions like these hold immense potential for reducing the societal and individual burden of chronic diseases. By targeting aging itself rather than isolated symptoms, TPE-IVIG therapy represents a novel modality that could extend not only lifespan but, crucially, healthspan, enabling people to live more vibrant, disease-free years. The emerging era of precision plasma therapeutics promises exciting developments in our quest to decode and combat the biology of aging.
Subject of Research: People
Article Title: Multi-omics Analysis Reveals Biomarkers that Contribute to Biological Age Rejuvenation in Response to Therapeutic Plasma Exchange
News Publication Date: 28-May-2025
Web References:
- https://onlinelibrary.wiley.com/doi/10.1111/acel.70103
- http://dx.doi.org/10.1111/acel.70103
- http://www.circulate.health
References:
Multi-omics Analysis Reveals Biomarkers that Contribute to Biological Age Rejuvenation in Response to Therapeutic Plasma Exchange, Aging Cell, 2025.
Keywords:
Health and medicine, Omics, Clinical trials, Preventive medicine
